Background. Human immunodeficiency virus (HIV)-infected individuals are at increased risk of chronic kidney disease (CKD). Human immunodeficiency virus infection, traditional CKD risk factors, and combination antiretroviral therapy (cART) may all contribute.
Human immunodeficiency virus (HIV)-infected individuals are at increased risk of developing chronic kidney disease (CKD) [1] [2] [3] . The pathogenesis of CKD in HIV-infected individuals is multifactorial: exposure to HIV viremia, chronic systemic inflammation, and potentially nephrotoxic antiretroviral drugs and co-medications, as well as traditional cardiovascular disease (CVD) and renal risk factors such as hypertension, diabetes, and smoking, may affect glomerular, tubulo-interstitial, and renovascular integrity [4] [5] [6] [7] [8] . Moreover, exposure to tenofovir disoproxil fumarate (TDF) may cause proximal renal tubular dysfunction, which in most cases remains subclinical but in a small proportion of patients presents as Fanconi's syndrome [9] . Furthermore, exposure to TDF, atazanavir, indinavir, and lopinavir has been associated with an increased risk of CKD [6, 7, 10] . Both proximal renal tubular dysfunction and/or estimated glomerular filtration rate (eGFR) decline may improve following discontinuation of these agents [11] [12] [13] [14] [15] [16] , and combination antiretroviral therapy (cART) switches are increasingly used in clinical practice to reduce the risk of renal disease progression in patients with proximal renal tubular dysfunction, CKD, or eGFR decline.
Albuminuria and proximal renal tubular dysfunction are more prevalent in HIV-infected individuals compared with HIV-uninfected controls [8, 17, 18] , and kidney disease progression is particularly common in black patients with CKD [19] . Although similar rates of GFR decline have been reported for HIV-infected and HIV-uninfected persons [20, 21] , these studies included mainly black patients with high rates of hepatitis C virus (HCV) infection. We analyzed and compared the prevalence and determinants of renal impairment, albuminuria, proximal renal tubular dysfunction, and changes in eGFR and albuminuria over time in predominantly virologically suppressed HIV-infected and otherwise highly comparable HIVuninfected AGE h IV Cohort Study participants.
METHODS

Study Population and Laboratory Evaluations
The AGE h IV Cohort Study is an ongoing, prospective, comparative, cohort study. Between 2010 and 2012, 598 HIV type 1-infected individuals were recruited from the HIV outpatient clinic of the Academic Medical Center in Amsterdam, the Netherlands. Five hundred fifty HIV-uninfected individuals with similar sociodemographic and behavioral characteristics were recruited from the sexual health clinic and the Amsterdam Cohort Studies on HIV/AIDS at the Amsterdam Public Health Service. Participants undergo biennial screening for age-associated comorbidities and organ dysfunction by physical examination, laboratory testing, and completion of self-administered questionnaires. Details concerning study procedures have previously been published [22] . Detailed information concerning HIV infection and ART history, including historically measured and recorded body weight, was obtained from the HIV Monitoring Foundation registry [23] . All participants provided written informed consent, and the study was approved by the local ethics review board. The protocol is registered at ClinicalTrials.gov (NCT01466582).
For the present analysis, we included data collected at baseline and follow-up study visits up to September 2016.
Plasma phosphate and creatinine, as well as urinary creatinine, albumin, and total protein (Roche Diagnostics) were quantified in randomly obtained fresh samples. Urinary retinol-binding protein (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay; lower limit of detection 6.0 μg/L [24] ) and phosphate (Dimension EXL AutoAnalyser, Siemens) were analyzed in stored (−80°C) samples obtained at baseline.
Definitions and Statistical Analyses
Group comparisons were performed using Student's t test, Wilcoxon rank-sum test, and χ 2 tests where appropriate. Correlations were calculated using Spearman's correlation coefficient (rho). We used multiple imputation by chained equations to impute missing baseline covariates, creating 10 imputed datasets (see Supplementary Materials). Analyses were performed using Stata version 12 (StataCorp). P values < .05 were considered statistically significant; all tests were 2-sided.
Baseline Analyses
The serum creatinine-based CKD Epidemiology Collaboration (CKD-EPI) equation was used to calculate eGFR. We defined renal impairment as eGFR <60 mL/min/1.73m 2 and albuminuria as urinary albumin/creatinine ratio ≥3 mg/mmol. We considered retinol-binding protein and fractional excretion of phosphate markers of proximal renal tubular dysfunction; proximal renal tubular dysfunction was defined as retinol-binding protein/creatinine ratio >2.93 μg/mmol and/or fractional excretion of phosphate >20% in persons with a plasma phosphate concentration <0.8 mmol/L [25, 26] . In individuals with at least 2 study visits, we defined CKD as the presence of albuminuria and/or renal impairment at both the first and second study visit [27] .
We investigated whether HIV was independently associated with renal impairment, albuminuria, and proximal renal tubular dysfunction at baseline using multivariable linear regression analysis. All multivariable models were adjusted for predefined potential confounders, including traditional risk factors for CKD: age, sex, being of African descent, cigarette smoking, chronic HCV infection (defined as detectable HCV RNA), hypertension, diabetes mellitus, and the level of low-density lipoprotein and statin use as markers of dyslipidemia. Biologically plausible interactions were investigated and included in the models if P interaction < .10. In the HIV-infected study group, traditional CKD risk factors, markers of inflammation (high-sensitivity C-reactive protein [hsCRP]), coagulation (D-dimer), immune activation (soluble [s]CD14 and sCD163), HIV-disease characteristics, and exposure to specific antiretroviral drugs were also considered as potential determinants of renal impairment, albuminuria, and proximal renal tubular dysfunction.
Longitudinal Analyses
Because several antiretroviral drugs are known to affect tubular function and/or inhibit tubular creatinine excretion [7] , for the purpose of our longitudinal analyses, HIV-infected individuals were censored at the time of any cART modification. The HIVuninfected participants were censored at HIV seroconversion or at initiation of preexposure prophylaxis.
We used linear mixed effects models with random intercept to generate eGFR slopes. Rapid eGFR decline was defined as an average yearly eGFR decline of at least 5 mL/min/1.73 m 2 with the most recent eGFR <90 mL/min/1.73 m 2 [28] . Worsening albuminuria was defined as an average yearly increase in albumin/creatinine ratio of at least 10% accompanied by a change in albuminuria category from <3 to ≥3 mg/mmol or from ≤30 to >30 mg/mmol [29] . We tested whether being HIV infected and remaining on unmodified cART was associated with rapid eGFR decline or worsening albuminuria in multivariable logistic regression models, adjusted for the same predefined potential confounders used for baseline analyses, as well as diagnosed CVD at baseline. We also assessed whether albuminuria and/ or proximal renal tubular dysfunction present at baseline were associated with rapid eGFR decline. Within the HIV-infected group, traditional CKD risk factors, markers of inflammation, coagulation, immune activation, HIV-disease characteristics, and exposure to specific antiretroviral drugs were explored as potential determinants of worsening albuminuria and rapid eGFR decline.
As a sensitivity analysis, we repeated the longitudinal analyses, now also including HIV-infected individuals who had their cART regimens modified.
RESULTS
Baseline Characteristics
In total, 596 HIV-infected and 544 HIV-uninfected individuals with data on eGFR at baseline were included in the analyses. Study participants were predominantly men who have sex with men, with a median age of 52.5 years (interquartile range [IQR] = 48.1-58.9). Compared with HIV-uninfected individuals, HIV-infected individuals were more likely to be of African descent and current smokers. Of the HIV-infected participants, 95.0% were on cART; 73.3% of all HIV-infected individuals were on TDF, and 41.7% were on a protease inhibitor (PI) at baseline ( Table 1) .
Prevalence of Renal Abnormalities
Renal impairment, albuminuria, and proximal renal tubular dysfunction were each significantly more prevalent in Abbreviations: Ab, antibody; (c)ART, (combination) antiretroviral therapy; HCV, hepatitis C virus; hsCRP, high-sensitivity C-reactive protein; HIV, human immunodeficiency virus; LDLc, low density lipoprotein cholesterol; SBP, systolic blood pressure; sCD14, soluble CD14; sCD163, soluble CD163.
a Hypertension is defined as a systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg, using the mean of the second and third of 3 seated measurements with a 1-minute interval after 5-minute rest, and/or the use of antihypertensive drugs.
b Diabetes mellitus is defined as glycated hemoglobin levels ≥48 mmol/mol and/or elevated blood glucose levels (nonfasting ≥11.1 mmol/L, fasting ≥7.0 mmol/L) and/or the use of antidiabetic medication.
c Cardiovascular disease is defined as self-reported and validated diagnosis of angina pectoris, myocardial infarction, ischemic cerebrovascular disease, angina pectoris, or peripheral arterial insufficiency.
d Severe immunodeficiency is defined as CD4 count <100 cells/mm 3 .
e Nadir body weight is the lowest ever measured body weight after HIV diagnosis, recorded by the HIV Monitoring Foundation registry.
HIV-infected compared with HIV-uninfected study participants ( Table 2 ). The albumin/creatinine ratio was significantly correlated with the retinol-binding protein/creatinine ratio in the HIV-infected study group (Spearman's rho = 0.44; P < .001), whereas the correlation was less strong in the HIVuninfected study group (Spearman's rho = 0.09; P = .05). The prevalence of renal impairment was highest among those historically exposed to TDF (16.4%) compared with those never (4.7%) or currently (2.8%) exposed to TDF, whereas the differences between these same 3 HIV-infected subgroups were less pronounced for albuminuria and proximal renal tubular dysfunction ( Figure 1 ). In multivariable logistic regression analyses, adjusted for age, sex, being of African descent, cigarette smoking, chronic HCV infection, hypertension, diabetes, and dyslipidemia, HIV infection was independently associated with renal impairment (adjusted odds ratio [aOR] = 2.1; 95% confidence interval [CI] = 1.0-4.4; P = .05), albuminuria (aOR = 5.8; 95% CI = 3.7-9.0; P < .001), and proximal renal tubular dysfunction (aOR = 7.1; 95% CI = 4.9-10.2; P < .001). Independent determinants of renal impairment, albuminuria, and proximal renal tubular dysfunction in the HIV-infected group are listed in Table 3 . Traditional CKD risk factors were independently associated with all 3 markers of abnormal renal function. Older age was independently associated with each of the assessed markers, whereas cigarette smoking was independently associated with a higher likelihood of albuminuria. Higher sCD14 levels were borderline significantly (P = .06) associated with a higher likelihood of renal impairment and significantly associated with albuminuria (but not proximal renal tubular dysfunction), but no associations were found with sCD163, hsCRP, or D-dimer. Proximal renal tubular dysfunction was associated with a low nadir body weight (ie, lowest recorded body weight after HIV diagnosis), exposure to PI, and cumulative exposure to TDF. Ninety (18.3%) of 491 HIV-infected and 20 (4.2%) of 472 HIV-uninfected individuals with sufficient available data had albuminuria and/or eGFR <60 mL/min/1.73 m 2 both at baseline and the year 2 study visit and thus fulfilled the Kidney Disease Improving Global Outcomes criteria for CKD (P < .001) [27] .
Longitudinal Analysis
A total of 377 HIV-infected individuals with a median follow-up of 3.9 years (IQR = 2.1-3.9) and 479 HIV-uninfected individuals with a median follow-up of 4.1 years (IQR = 3.9-4.3) were included in the longitudinal analyses. Of these, 229 HIV-infected (60.7%) and 400 HIV-uninfected (83.5%) individuals contributed data from 3 study visits, and the remainder contributed data from 2 study visits. Reasons for incomplete follow-up are included in Supplementary Figure 1 ; 106 HIVinfected individuals were censored for the analysis at the first follow-up study visit, and another 79 were censored at the second follow-up study visit after having discontinued or modified their baseline cART regimen. Pre-and postswitch cART regimens are summarized in Supplementary Table 1 ; modification of cART included discontinuation of TDF in 42 cases (23.5%).
The unadjusted eGFR slope was −1.36 (95% CI = −1.59 to −1.14) mL/min/1.73m 2 /year in HIV-infected individuals and −0.71 (95% CI = −.90 to −.51) mL/min/1.73m 2 /year in HIVuninfected individuals; eGFR decline was significantly greater in HIV-infected patients (−0.66; 95% CI = −.96 to −.36 mL/ min/1.73m 2 /year; P < .001). After adjustment for age, sex, being of African descent, cigarette smoking, chronic HCV infection, diabetes mellitus, dyslipidemia, hypertension, and baseline CVD, HIV-positive status remained significantly associated with greater eGFR decline (−0.56; 95% CI = −.87 to −.24 mL/ min/1.73m 2 /year; P = .001) (Figure 2 ). Rapid eGFR decline was more common in HIV-infected patients (5.8%) than controls (2.3%; P = .008). After adjustment for age, sex, being of African descent, cigarette smoking, and chronic HCV infection, HIV infection remained associated with a greater likelihood of rapid eGFR decline (aOR HIV = 2.2; 95% CI = 1.0-4.7; P = .04). Further adjustment for diabetes, dyslipidemia, hypertension, and baseline CVD only slightly attenuated the association (aOR HIV 2.1; 95% CI = 1.0-4.5; P = .06). Worsening albuminuria was more common in the HIV-infected group (11.6% vs 5.0%; P < .001). After adjustment for age, sex, being of African descent, cigarette smoking, and chronic HCV infection, those with HIV infection were at increased odds of worsening albuminuria (aOR HIV = 2.4; 95% CI = 1.4-4.0; P = .001), which persisted after additional adjustment for hypertension, diabetes, dyslipidemia, baseline CVD, and baseline eGFR (aOR HIV = 2.3; 95% CI = 1.3-4.0; P = .003).
Baseline albuminuria was predictive for rapid eGFR decline in HIV-uninfected participants (OR 7.2; 95% CI = 1.8-29.0; P = .005) but not significantly predictive for rapid eGFR decline in HIV-infected study participants (OR = 1.6; 95% CI = 0.6-4.1; P = .32; P interaction = .08). Baseline proximal renal tubular dysfunction was borderline significantly predictive of rapid eGFR decline in the combined cohort (OR = 2.1; 95% CI = 1.0-4.6; P = .06). This association did not significantly differ by HIVstatus (P interaction = .93) and was no longer statistically significant after adjusting for age, sex, being of African descent, cigarette smoking, and chronic HCV infection (aOR = 1.9; 95% CI = .8-4.2; P = .13).
In HIV-infected participants, current exposure to atazanavir and a history of more prolonged CD4 T-cell lymphopenia <100 cells/mm 3 were independently associated with a greater likelihood of rapid eGFR decline. Exposure to TDF was not independently associated with rapid eGFR decline (aOR TDF = 1.6; 95% CI = .5-5.2; P = .41). Smoking and lower eGFR at baseline were independently associated with worsening albuminuria (Table 4) . Baseline levels of markers of immune activation and inflammation were not associated with rapid eGFR decline or worsening albuminuria. We repeated the longitudinal analyses, now also including HIV-infected individuals who had their cART regimens modified. In the fully adjusted model, HIV infection was independently associated with an increased risk of rapid eGFR decline (aOR HIV = 3.2; 95% CI = 1.6-6.4; P = .001). Within the HIV-infected group, exposure to TDF at baseline was not associated with rapid eGFR decline in either unadjusted (OR = 0.78; 95% CI = 0.4-1.6; P = .50) or adjusted analysis (aOR = 0.80; 95% CI = .37-1.73; P = .58). In an unadjusted model with random intercept and random slope, treated HIV infection was associated with greater eGFR decline (−1.59, 95% CI = −1.82 to −1.37 mL/min/1.73m 2 /year; compared with −0.69, 95% CI = −.91 to −.48 mL/min/1.73m 2 /year in HIV-uninfected controls; P = .001). In the fully adjusted model, HIV-positive status was associated with significantly greater eGFR decline (−0.78; 95% CI = −1.10 to −.46] mL/min/1.73m 2 /year; P < .001).
DISCUSSION
We compared the prevalence and progression of chronic kidney disease in middle-aged individuals with mostly well-controlled HIV infection and behaviorally and sociodemographically similar HIV-uninfected controls. Human immunodeficiency virus infection was independently associated with renal impairment, albuminuria, and proximal renal tubular dysfunction. Moreover, HIV-infected individuals on cART had greater eGFR decline and were more likely to develop rapid eGFR decline and worsening albuminuria during follow-up than HIV-uninfected individuals.
These results are consistent with previous studies reporting a higher prevalence of CKD and end-stage renal disease in Definitions: Renal impairment, eGFR <60 mL/min/1.73m 2 ; albuminuria, albumin/creatinine ratio ≥3 mg/mmol; proximal renal tubular dysfunction, retinol binding protein/creatinine ratio >2.93 µg/mmol and/or fractional excretion of phosphate >20% with plasma phosphate <0.8 mmol/L. Covariates tested but found not to be independently associated with any of the 3 categories (and thus not shown in the table): sex, ethnicity, hepatitis C virus infection, dyslipidemia, use of angiotensin-converting enzyme inhibitors, body mass index, waist-to-hip ratio, soluble CD163, high-sensitivity C-reactive protein, D-dimer, nadir CD4 T-cell count, duration of CD4 T-cell lymphopenia <200 cells/mm 3 , history of AIDS, human immunodeficiency virus load >200 copies/mL, cumulative exposure to any protease inhibitor, lopinavir, indinavir, darunavir, or atazanavir, time since stopping tenofovir disoproxil fumarate (TDF) (in those no longer using TDF), and co-exposure to a protease inhibitor and TDF.
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; OR, odds ratio; sCD14, soluble CD14; TDF, tenofovir disoproxil fumarate.
HIV-infected patients compared with the general population [1] [2] [3] 30] . In line with studies performed within HIV-infected populations [8, 31] , traditional and modifiable risk factors were important determinants of CKD in HIV-infected study participants. However, we could not completely explain the association between HIV infection and prevalence and progression of CKD by the higher prevalence of traditional CKD risk factors. Chronic inflammation is likely to be involved in the pathophysiology of CVD in HIV-infected individuals [32] , and a recent study reported an association between inflammatory processes, mild renal impairment, and proteinuria in HIVinfected men [4] . We observed a trend for higher levels of sCD14, a marker of monocyte activation previously associated with CVD in HIV-infected patients [32] , to be associated with the presence of renal impairment and albuminuria, but not with rapid eGFR decline or worsening albuminuria. These findings do not strongly support, but also cannot definitely rule out, persistent immune activation to play a role in kidney disease pathogenesis in HIV-infected patients on treatment.
Individuals with a history of advanced HIV disease were at increased risk of prevalent and progressive renal disease. A lower nadir body weight was an independent predictor of prevalent renal impairment, albuminuria, and proximal renal tubular dysfunction, and past immunodeficiency was also independently associated with rapid eGFR decline. Advanced immunodeficiency and viral replication are risk factors for HIV-associated nephropathy and HIV-associated immune complex kidney disease, which are important causes of renal impairment, albuminuria, and kidney disease progression [33] [34] [35] . In addition, these individuals may have received older nephrotoxic antiretrovirals as well as nephrotoxic medications for the treatment of opportunistic infections.
Human immunodeficiency virus infection was independently associated with proximal renal tubular dysfunction, which was particularly prevalent in HIV-infected patients currently or historically exposed to TDF. The relationship between TDF and proximal renal tubular dysfunction is well recognized. Tenofovir disoproxil fumarate exposure has been associated with proximal renal tubular dysfunction in observational studies [12, 36] , and increased tubular biomarkers have been observed in randomized controlled trials of TDF versus abacavir [37] or tenofovir alafenamide (TAF) [38] . Consistent with data for treatment-limiting tubulopathy [39] , cumulative exposure to TDF was a risk factor for proximal renal tubular dysfunction in our HIV-infected patients. Furthermore, the prevalence of proximal renal tubular dysfunction was similar in patients with current versus prior TDF exposure. The latter group more commonly had mildly reduced eGFR (60-89 mL/ min/1.73m 2 ), suggesting that TDF may have been discontinued because of renal concerns. Tenofovir disoproxil fumarate-associated proximal renal tubular dysfunction may be reversible [26, 40, 41] ; proximal renal tubular dysfunction in TDF recipients with reduced eGFR may in part be due to other etiologies that affect the tubulo-interstitium and thus persist upon TDF discontinuation.
The long-term consequences of mild to moderate proximal renal tubular dysfunction (and especially TDF-associated proximal renal tubular dysfunction) in terms of eGFR decline are not entirely clear [9] . We observed a weak association between proximal renal tubular dysfunction and subsequent rapid eGFR decline, but this may reflect limited statistical power, relatively short follow-up, and a limited number of data points. Future longitudinal analyses within the cohort may provide more clarity.
The high prevalence of albuminuria in HIV-infected patients is likely multifactorial. In a proportion of individuals, it may be due to structural or functional disorders in the context of the metabolic syndrome or diabetes mellitus. However, after adjusting for hypertension, dyslipidemia, diabetes, and smoking (all factors contributing to the metabolic syndrome), HIV status remained independently associated with albuminuria, indicating that the difference in prevalence cannot be completely explained Abbreviations: cART, combination antiretroviral therapy; eGFR, estimated glomerular filtration rate; OR, odds ratio.
a Average eGFR decline ≥5 mL/min/1.73m 2 /year, with the last eGFR measurement <90 mL/min/1.73m 2 .
b Average albumin/creatinine ratio increase ≥10%/year, accompanied by a change in albuminuria category (<3 to ≥3 mg/mmol, or ≤30 to >30 mg/mmol).
by these factors. In a subset of HIV-infected individuals, albuminuria may be a reflection of tubular dysfunction: rather than increased glomerular permeability, modest increases in albuminuria may be explained by decreased tubular reabsorption of small quantities of albumin that are present in the urine of people with normal glomerular function [27, 42] . Consistent with this interpretation, data from clinical trials have shown greater amounts of urinary albumin with TDF-versus TAF-containing cART [38] and reduction in albuminuria after switching from TDF to TAF [43] . Furthermore, we found a considerable overlap of risk factors for albuminuria and proximal renal tubular dysfunction in our cohort and a significant correlation between the retinol-binding/creatinine ratio and the albumin/creatinine ratio in the HIV-infected study group. In the HIV-infected study group, retinol-binding proteinuria was observed considerably more often than albuminuria (37.6% vs 24.4%), supporting the use of this more sensitive marker to diagnose proximal renal tubular dysfunction, at least in research settings. Lastly, advanced CKD may be accompanied by proximal renal tubular dysfunction and increased excretion of low-molecular-weight proteins such as retinol-binding protein due to the toxic effects to the proximal tubules of medium-to-high-molecular-weight proteins in the ultrafiltrate [27, 44] . This study is limited by a relatively short follow-up duration. Individuals who changed cART or who discontinued potentially nephrotoxic antiretrovirals such as TDF were censored in our longitudinal analyses. In our cohort, cART modification is likely to have particularly included TDF discontinuation in HIV-infected patients with or at greatest risk for CKD, and this may have led to an underestimation of the effects of (TDF-) treated HIV infection on eGFR slopes and worsening albuminuria. Indeed, additional models that included all treated HIV-infected patients regardless of cART modification showed stronger associations between treated HIV infection and eGFR decline. This observation also suggests that greater renal function decline may be observed in populations in whom renal function is not routinely monitored. Our cohort predominantly consists of men who have sex with men. This may limit the generalizability of our findings to other populations, particularly women and people of African descent.
In these middle-aged individuals, HIV infection was independently associated with renal impairment, albuminuria, and proximal renal tubular dysfunction. Moreover, HIV-infected individuals on (predominantly TDF-containing) cART were also more likely to experience eGFR decline and worsening albuminuria during follow-up. This may in part be due to exposure to certain antiretroviral drugs; the nephrotoxic potential of antiretroviral regimens should be considered in the management of HIV infection. Continued follow-up of our cohort participants may clarify the role of persistent immune activation during treatment, as well as the possible impact of proximal renal tubular dysfunction on renal function decline over time.
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